Torrent Pharma enters into licensing agreement with Reliance Life Sciences for three biosimilars

January 6, 2015 9:46 AM

Torrent Pharmaceuticals Ltd. last week announced that it has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing 3 biosimilars in India – Rituximab, Adalimumab and Cetuximab.

As per the agreement, Reliance Life Sciences will develop and supply these products to Torrent Pharma after obtaining all necessary regulatory approvals. Torrent Pharma will be the only company to market these biosimilars in India other than Reliance Life Sciences.

Torrent Pharma forayed into the oncology and dermatology segments in 2011-12 with the launch of exclusive divisions and has since gained a strong position in these segments. The licensing agreement with Reliance Life Sciences is expected to significantly boost its presence in these segments in the coming years.

Rituximab and Cetuximab cater to the oncology segment and are used in the treatment of various cancers like leukemia, lymphoma, colorectal, head and neck cancers. Adalimumab is the most preferred therapy for the treatment of auto immune disorders like rheumatoid arthritis, psoriasis and IBD.

As per the terms of the agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of ten years.

Torrent Pharma has in the past launched the biosimilar Darbepoetin under the brand name of Darbatitor which is used during dialysis.

Source: Torrent press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!